WHIM综合征:从机制到向治疗 - - 进步塑造临床护理的进展
Rahim Z Miller1,2, Christoph B Geier3,4, Jacob R Bledsoe5
1Division of Allergy and Immunology, Department of Pediatrics and Medicine, Morsani College of Medicine, University of South Florida at Johns Hopkins All Children's Hospital.
,低型球蛋白血症,感染和骨髓灰质炎综合征 (WHIM) 是一种联合免疫缺陷,通常是由增加的CXCR4信号引起的. 一种新的口服CXCR4抗剂在改善中性粒细胞和淋巴细胞数量以及减少感染方面显示出有前途.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
背景情况:
- ,低型球蛋白血症,感染和骨髓灰质炎综合征 (WHIM) 是一种自体主导的综合免疫缺陷 (CID).
- 它通常是由增加的CXCR4通路信号引起的,导致中性质衰竭和延迟诊断.
- 诊断可能是具有挑战性的,因为穿透能力不完整,需要专门的骨髓评估.
研究的目的:
- 审查当前对WHIM综合征的理解和管理.
- 突出诊断和治疗的最新进展,包括新的遗传发现和治疗目标.
- 讨论CXCR4对抗性对WHIM综合征的影响.
主要方法:
- 关于WHIM综合征,CXCR4信号传递和治疗干预的最新文献的综述.
- 对口服CXCR4抗剂临床试验数据的分析.
- 在人类和小鼠模型中检查机械学研究.
主要成果:
- 新生儿对低胸膜移徙T细胞的查可以识别一些患有WHIM综合征的婴儿,从而导致更早的诊断和更好的结果.
- CXCR4突变的遗传谱比以前认为的更广泛.
- 口服CXCR4抗剂在增加循环中性粒细胞和淋巴细胞,减少感染,并可能导致回归方面表现出有效性.
- 机械研究揭示了CXCR4过度激活如何损害造血干细胞的输出和白细胞的贩运.
结论:
- 提高意识,新生儿查和改善诊断对于及时识别WHIM综合征至关重要.
- 美国食品和药物管理局批准口服CXCR4抗剂标志着一个重要的治疗进步.
- 由于幽默缺陷,抗病毒防御功能受损和恶性瘤的风险,WHIM综合征需要长期监测.
- 需要进一步的研究来探索CXCR4对抗性的更广泛应用.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Abnormal Proliferation
Treatment Resistant Cancers
Tumor Immunotherapy
